Trial Profile

An Open-Label Study of ALTO-100 in Adults With Major Depressive Disorder (MDD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALTO-100 (Primary)
Indications Major depressive disorder
Focus Adverse reactions; Therapeutic Use
Sponsors Alto Neuroscience

Most Recent Events

14 May 2025 Results presented in the Alto Neuroscience media release.
14 May 2025 According to an Alto Neuroscience media release, Company presented additional analyses of the ALTO-100 MDD Phase 2b trial at the Society of Biological Psychiatry (SOBP) Annual Meeting highlighting the utilization of an EEG-based biomarker to account for potential placebo responders.
13 Aug 2024 According to an Alto Neuroscience media release, Investor Day focused on ALTO-100 planned for Sept 9, 2024 and topline data expected in October 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com